五个队列中多发性皮肤癌的发生频率与时间分布
3%的患者治疗过10种及以上皮肤癌,贡献了22%的总治疗次数。
要点
- 3%的患者治疗≥10种皮肤癌,占全部皮肤癌治疗的22%。
- 数据格式改进有助于识别多发皮肤癌高危个体及可减少年度监测者。
核心结论
- 近半数皮肤癌患者会再发至少一种皮肤癌,少数高危患者贡献大量治疗负担。
研究设计与样本
- 纵向理赔与电子健康记录队列研究,合并队列含5,508,374例患者,共13,102,123次皮肤癌治疗,采用验证过的表型计数个体皮肤癌。
主要发现
- 3%的患者治疗过10种及以上皮肤癌,贡献了合并队列中22%的全部皮肤癌治疗。
关键数值与推荐
- 高危亚组:治疗≥10种皮肤癌的患者占3%,贡献22%的总治疗次数。
临床怎么用
- 临床应关注皮肤癌患者的再发风险,尤其在初次治疗后2年内加强随访。
- 对治疗≥10种皮肤癌的高危患者需强化监测,而对低风险患者可考虑个体化调整年度监测策略。
局限性
- 缺乏高质量的皮肤癌类型数据。
- 现有数据库与健康记录并非为捕获皮肤癌多发性而设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients will develop more than one skin cancer; however, most research to date has examined only case status. OBJECTIVE: Describe the frequency and timing of the treatment of multiple skin cancers in individual patients over time. METHODS: We conducted a longitudinal claims and electronic health record-based cohort study to examine the frequency of skin cancer multiplicity. We used a validated phenotype for counting individual skin cancers. RESULTS: Our combined cohort included 5,508,374 patients and 13,102,123 total skin cancers treated. Forty-three percent of patients treated for skin cancer were treated for more than one skin cancer, most within 2 years of the initial skin cancer. A subset of 3% of patients were treated for 10 or more skin cancers and contributed 22% of all skin cancers treated in the combined cohort. LIMITATIONS: High-quality data on skin cancer types were not available. Databases and health records are not designed to capture skin cancer multiplicity well. CONCLUSIONS: Nearly half of patients treated for skin cancer will develop at least one more. Better data formatting will allow for improved granularity in identifying individuals at high risk for multiple skin cancers and those unlikely to benefit from continued annual surveillance.
引用
- Wheless L, Liao KP, Zheng S, et al. Frequency and timing of multiple skin cancer development in five cohorts. J Am Acad Dermatol. 2025. PMID: 39929309. doi:10.1016/j.jaad.2024.12.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。